Key Proteo Presents Wilson Disease Pilot Study Updates
Exciting News from Wilson Aarhus 2024 Symposium
Sihoun Hahn, MD, PhD, our Chief Medical Officer and Co-Founder, presented updates on a large 22,000-sample pilot study for modernized newborn screening using Key Proteo’s Immuno-SRM.
Key Takeaways:
APT7B peptide target quantified with very high sensitivity and specificity.
Exceptionally low false positive rate and invalid rate. No true false negatives.
Peptide concentrations stable across weight, gender, and ethnicity.
LC-MS proteomics proven feasible for newborn screening of Wilson Disease from standard DBS specimens.
Early detection and intervention is critical. Key Proteo’s Immuno-SRM technology reveals the previously undetectable using existing LC-MS workflows.
Key Proteo is grateful to the Wilson Aarhus Symposium for featuring cutting-edge Wilson Disease research. Kudos to all presenters, attendees and organizers!
#WilsonDisease #WilsonDiseaseAssociation #MedicalResearch #Proteomics #NewbornScreening #HealthcareInnovation #WilsonAarhus2024 #KeyProteo #EarlyDetection
